Dose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials
ROCKVILLE, Md., Jan. 6, 2025 /PRNewswire/ -- Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has completed dose escalation enrollment stages for both